The findings confirm that allosteric inhibition of integrase is clinically viable, validating a new antiviral drug class.
NMRA-898 is structurally distinct from NMRA-861 and is the second M4 PAM in Neumora’s M4 franchise; both programs have potential best-in-class pharmacology No convulsions observed in pre-clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback